A randomized clinical trial indicates that neither metformin nor ursodeoxycholic acid (UDCA) significantly improves recovery from postacute sequelae of SARS-CoV-2 (PASC) compared to placebo, highlighting the ongoing challenge of finding effective treatments for Long COVID.